Jack Yalowich, PhD

Professor

Pharmaceutics and Pharmacology

Research Areas: Cancer, Infectious Diseases, The Division of Pharmaceutics & Pharmacology

532 Parks Hall

Professional Interests

Dr. Yalowich’s lab focuses on mechanisms of action and resistance to a class of anticancer agents known as DNA topoisomerase IIα (TOP2α; 170 kDa ) inhibitors, such as the anticancer agent etoposide. Ongoing projects characterize alternative RNA processing/intronic polyadenylation of TOP2α pre-mRNA that results in formation of a 90 kDa truncated form of TOP2α in acquired resistance to etoposide. Strategies to circumvent drug resistance involve CRISPR/Cas9 gene editing to restore proper RNA splicing function in resistant cells. In addition, the role of micro-RNAs as determinants of anticancer drug resistance is under investigation. Finally, the Yalowich lab actively collaborates with Dr. Mark-Mitton-Fry from the Division of Medicinal Chemistry and Pharmacognosy to evaluate the mechanisms of action and efficacy of newly synthesized Novel Bacterial Topoisomerase Inhibitors (NBTIs).

Biography

Dr. Yalowich’s educational background includes a B.A. in Biology and Chemistry from Lehigh University, a Ph.D. in Biochemical Pharmacology from S.U.N.Y Buffalo studying anticancer drugs that target the essential enzyme Thymidylate synthase, and postdoctoral training at the Medical College of Virginia (antifolate studies) and University of Florida, evaluating DNA topoisomerase II inhibitors where his research focus has remained. His first academic position was at St. Jude Children’s Hospital in Memphis, TN as an Assistant Member, followed by a position as Assistant Professor and tenured Associate Professor in the Department of Pharmacology and Chemical Biology at the University of Pittsburgh School of Medicine. In 2010, he joined the faculty of The Ohio State University College of Pharmacy as Professor (and Chair 2015-2017) in the Division of Pharmacology (since 2020 the Division of Pharmaceutics and Pharmacology). Aside from maintaining a productive and funded research enterprise, Dr. Yalowich has chaired two separate NIH peer-review panels and serves on the executive committee for the Division of Cancer Pharmacology at the American Society for Pharmacology and Experimental Therapeutics.

View My Bibliography from NCBI

Education

1974 - BA, Chemistry & Biology, Lehigh University
1980 - PhD, Biochemical Pharmacology, State University of New York at Buffalo
1980-1983, Postdoctoral Fellow, Department of Medicine, Medical College of Virginia

Honors

2017 - Present: Secretary-Treasurer; Division for Cancer Pharmacology; American Society for Pharmacology and Experimental Therapeutics
2016 - Present: Editorial Board; Journal of Pharmacology and Experimental Therapeutics
2015-2017: Chair; Division of Pharmacology, College of Pharmacy, The Ohio State University
2012-2016: Chair; Molecular Targets for Cancer Intervention [ZRG BMCT-C (01)] study section, National Cancer Institute (NCI/NIH)
2004-2009: Chair (2007-2009) and Chartered Member; Basic Mechanism of Cancer Therapeutics (BMCT) study Section, National Cancer Institute (NCI/NIH)
1999-2005: Chair (2004 & 2005) and Member; Panel G: Experimental Therapeutics, Carcinogenesis, & Medicinal Chemistry study section, National Cancer Institute of Canada (NCIC)
1984-1986: Special Fellow; Leukemia Society of America

Publications

Circumvention of Topoisomerase IIα Intron 19 Intronic Polyadenylation in Acquired Etoposide-Resistant Human Leukemia K562 Cells, Molecular Pharmacology. 2024 Jul | journal-article. doi: 10.1124/molpharm.124.000868.
Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II β in Human Leukemia K562 Cells: Generation of a Resistance Phenotype, The Journal of Pharmacology and Experimental Therapeutics. 2024 May | journal-article. doi: 10.1124/jpet.123.002038.
Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs, Antimicrobial Agents and Chemotherapy. 2023 Oct | journal-article. doi: 10.1128/aac.00482-23.
Actions of a Novel Bacterial Topoisomerase Inhibitor against Neisseria gonorrhoeae Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks, International Journal of Molecular Sciences. 2023 Jul | journal-article. doi: 10.3390/ijms241512107.
Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II β Expression in Human Leukemia K562 Cells with Acquired Resistance to Etoposide, The Journal of Pharmacology and Experimental Therapeutics. 2023 Feb | journal-article. doi: 10.1124/jpet.122.001429.
Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase IIα, Cancers. 2022 Jun | journal-article. doi: 10.3390/cancers14133148.
Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA., Journal of medicinal chemistry. 2021 Oct | journal-article. doi: 10.1021/acs.jmedchem.1c01250.
CRISPR/Cas9 Genome Editing of the Human Topoisomerase IIα Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells., Molecular pharmacology. 2021 Jan | journal-article. doi: 10.1124/molpharm.120.000173.
Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus., ACS medicinal chemistry letters. 2020 Oct | journal-article. doi: 10.1021/acsmedchemlett.0c00428.
Novel bacterial topoisomerase inhibitors derived from isomannide., European journal of medicinal chemistry. 2020 Apr | journal-article. doi: 10.1016/j.ejmech.2020.112324.
Effects of DNA topoisomerase IIα splice variants on acquired drug resistance., Cancer drug resistance (Alhambra, Calif.). 2020 Feb | journal-article. doi: 10.20517/cdr.2019.117.
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase IIα in Human Leukemia K562 Cells with Acquired Resistance to Etoposide., Molecular pharmacology. 2019 Dec | journal-article. doi: 10.1124/mol.119.118315.
1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition., ACS infectious diseases. 2019 May | journal-article. doi: 10.1021/acsinfecdis.8b00375.
Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety., Bioorganic & medicinal chemistry letters. 2018 Jun | journal-article. doi: 10.1016/j.bmcl.2018.06.003.
Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones., Bioorganic & medicinal chemistry. 2018 Mar | journal-article. doi: 10.1016/j.bmc.2018.03.033.
The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIα (TOP2α/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2α/170 Isoform., Molecular pharmacology. 2018 Mar | journal-article. doi: 10.1124/mol.117.111567.
Capsicodendrin from Cinnamosma fragrans Exhibits Antiproliferative and Cytotoxic Activity in Human Leukemia Cells: Modulation by Glutathione., Journal of natural products. 2018 Feb | journal-article. doi: 10.1021/acs.jnatprod.7b00887.
Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform., The Journal of pharmacology and experimental therapeutics. 2016 Nov | journal-article. doi: 10.1124/jpet.116.237107.
Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform., The Journal of pharmacology and experimental therapeutics. 2015 Dec | journal-article. doi: 10.1124/jpet.115.228650.
TRIM72 modulates caveolar endocytosis in repair of lung cells., American journal of physiology. Lung cellular and molecular physiology. 2015 Dec | journal-article. doi: 10.1152/ajplung.00089.2015.
Experimental procedures to identify and validate specific mRNA targets of miRNAs., EXCLI journal. 2015 Jul | journal-article. doi: 10.17179/excli2015-319.
Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs., Bioorganic & medicinal chemistry. 2015 Apr | journal-article. doi: 10.1016/j.bmc.2015.04.022.
Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis., Phytochemistry. 2015 Jan | journal-article. doi: 10.1016/j.phytochem.2014.12.014.
Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)., Biochemical pharmacology. 2014 Dec | journal-article. doi: 10.1016/j.bcp.2014.12.008.
Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA., Bioorganic & medicinal chemistry. 2014 Sep | journal-article. doi: 10.1016/j.bmc.2014.09.014.
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei., Journal of natural products. 2014 Jun | journal-article. doi: 10.1021/np5002785.
The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II., Biochemical pharmacology. 2012 Oct | journal-article. doi: 10.1016/j.bcp.2012.09.023.
The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα., Biochemical pharmacology. 2012 Apr | journal-article. doi: 10.1016/j.bcp.2012.03.021.
Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents., Bioorganic & medicinal chemistry. 2011 Oct | journal-article. doi: 10.1016/j.bmc.2011.10.012.
Cadmium is a catalytic inhibitor of DNA topoisomerase II., Journal of inorganic biochemistry. 2011 Feb | journal-article. doi: 10.1016/j.jinorgbio.2011.02.007.
Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells., Molecular pharmacology. 2010 Nov | journal-article. doi: 10.1124/mol.110.068718.
Toxicity issues in cancer drug development., Current opinion in investigational drugs (London, England : 2000). 2010 Jun | journal-article. .
Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents., Bioorganic & medicinal chemistry. 2010 Apr | journal-article. doi: 10.1016/j.bmc.2010.04.028.
The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint., Molecular cancer therapeutics. 2010 Feb | journal-article. doi: 10.1158/1535-7163.mct-09-0627.
A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II., Bioorganic & medicinal chemistry. 2009 Nov | journal-article. doi: 10.1016/j.bmc.2009.11.048.
The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds., Bioorganic & medicinal chemistry. 2009 May | journal-article. doi: 10.1016/j.bmc.2009.04.072.
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds., Bioorganic & medicinal chemistry. 2008 Jan | journal-article. doi: 10.1016/j.bmc.2008.01.033.
Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha., Chemical research in toxicology. 2008 Jan | journal-article. doi: 10.1021/tx700341n.
A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors., Molecular pharmacology. 2007 Nov | journal-article. doi: 10.1124/mol.107.041624.
Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F., Free radical biology & medicine. 2007 Jul | journal-article. doi: 10.1016/j.freeradbiomed.2007.07.005.
c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase., Molecular pharmacology. 2006 Oct | journal-article. doi: 10.1124/mol.106.026575.
Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects., Anti-cancer drugs. 2006 Aug | journal-article. doi: 10.1097/01.cad.0000224442.78211.27.
A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone., Journal of chemical information and modeling. 2006 Jul | journal-article. doi: 10.1021/ci060056y.
Increased mutant frequencies in the HPRT gene locus of leukemia HL-60 cells treated with succinylacetone., Cell biology and toxicology. 2006 Jul | journal-article. doi: 10.1007/s10565-006-0171-4.
Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells., Chemical research in toxicology. 2006 Jul | journal-article. doi: 10.1021/tx0600595.
Mechanisms of cardiolipin oxidation by cytochrome c: relevance to pro- and antiapoptotic functions of etoposide., Molecular pharmacology. 2006 May | journal-article. doi: 10.1124/mol.106.022731.
Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II., Cancer chemotherapy and pharmacology. 2005 Jul | journal-article. doi: 10.1007/s00280-005-0040-5.
Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha., Molecular pharmacology. 2004 Dec | journal-article. doi: 10.1124/mol.104.004416.
Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase., Molecular pharmacology. 2004 Jul | journal-article. doi: 10.1124/mol.104.001784.
Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation., The Journal of biological chemistry. 2003 Nov | journal-article. doi: 10.1074/jbc.m309929200.
Direct evidence for recycling of myeloperoxidase-catalyzed phenoxyl radicals of a vitamin E homologue, 2,2,5,7,8-pentamethyl-6-hydroxy chromane, by ascorbate/dihydrolipoate in living HL-60 cells., Biochimica et biophysica acta. 2003 Mar | journal-article. doi: 10.1016/s0304-4165(02)00509-3.
Anti-/pro-oxidant effects of phenolic compounds in cells: are colchicine metabolites chain-breaking antioxidants?, Toxicology. 2002 Aug | journal-article. doi: 10.1016/s0300-483x(02)00199-3.
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines., Molecular cancer therapeutics. 2001 Dec | journal-article. .
Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase., Cancer research. 2001 Nov | journal-article. .
Synthesis and biological activity of a photoaffinity etoposide probe., Bioorganic & medicinal chemistry. 2001 Jul | journal-article. doi: 10.1016/s0968-0896(01)00102-x.
Antioxidant mechanisms of nitric oxide against iron-catalyzed oxidative stress in cells., Antioxidants & redox signaling. 2001 Apr | journal-article. doi: 10.1089/152308601300185160.
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells., Molecular pharmacology. 2001 Mar | journal-article. doi: 10.1124/mol.59.3.453.
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells., The Journal of pharmacology and experimental therapeutics. 2000 Nov | journal-article. .
Regulation of DNA-dependent protein kinase activity by ionizing radiation-activated abl kinase is an ATM-dependent process., The Journal of biological chemistry. 2000 Sep | journal-article. doi: 10.1074/jbc.m004302200.
Myeloperoxidase-catalyzed phenoxyl radicals of vitamin E homologue, 2,2,5,7,8-pentamethyl- 6-hydroxychromane, do not induce oxidative stress in live HL-60 cells., Biochemical and biophysical research communications. 2000 Apr | journal-article. doi: 10.1006/bbrc.2000.2564.
Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach., Molecular pharmacology. 1999 Sep | journal-article. doi: 10.1124/mol.56.3.494.
Mechanisms of nitric oxide protection against tert-butyl hydroperoxide-induced cytotoxicity in iNOS-transduced human erythroleukemia cells., Biochemistry. 1999 Aug | journal-article. doi: 10.1021/bi9829229.
Induction of human breast cancer cell apoptosis from G2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2,3-diphenylcyclopropane., Biochemical pharmacology. 1999 Jan | journal-article. doi: 10.1016/s0006-2952(98)00289-5.
The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis., Anti-cancer drugs. 1999 Jan | journal-article. doi: 10.1097/00001813-199901000-00007.
The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II., Anti-cancer drugs. 1998 Jun | journal-article. doi: 10.1097/00001813-199806000-00014.
Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site., Molecular pharmacology. 1997 Nov | journal-article. doi: 10.1124/mol.52.5.839.
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II., Biochemical pharmacology. 1997 Jun | journal-article. doi: 10.1016/s0006-2952(97)00013-0.
Nitric oxide prevents oxidative damage produced by tert-butyl hydroperoxide in erythroleukemia cells via nitrosylation of heme and non-heme iron. Electron paramagnetic resonance evidence., The Journal of biological chemistry. 1997 May | journal-article. doi: 10.1074/jbc.272.19.12328.
Chemical synthesis and biological activity of a novel fluorescent etoposide derivative., Biochemical pharmacology. 1997 Mar | journal-article. doi: 10.1016/s0006-2952(96)00906-9.
Non-random peroxidation of different classes of membrane phospholipids in live cells detected by metabolically integrated cis-parinaric acid., Biochimica et biophysica acta. 1996 Sep | journal-article. doi: 10.1016/0005-2736(96)00083-1.
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells., Biochemical pharmacology. 1996 Aug | journal-article. doi: 10.1016/0006-2952(96)00338-3.
The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells., Anti-cancer drugs. 1996 Jul | journal-article. doi: 10.1097/00001813-199607000-00011.
Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells., Molecular pharmacology. 1996 Feb | journal-article. .
Reduction of phenoxyl radicals of the antitumour agent etoposide (VP-16) by glutathione and protein sulfhydryls in human leukaemia cells: Implications for cytotoxicity., Toxicology in vitro : an international journal published in association with BIBRA. 1996 Feb | journal-article. doi: 10.1016/0887-2333(95)00106-9.
Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C., Molecular pharmacology. 1995 Nov | journal-article. .
Induction of apoptosis in murine and human neuroblastoma cell lines by the enediyne natural product neocarzinostatin., The Journal of pharmacology and experimental therapeutics. 1995 Oct | journal-article. .
A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane)., Biochemical pharmacology. 1995 Sep | journal-article. doi: 10.1016/0006-2952(95)00218-o.
Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide., Proceedings of the National Academy of Sciences of the United States of America. 1995 May | journal-article. doi: 10.1073/pnas.92.10.4452.
Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants., Toxicology and applied pharmacology. 1995 Apr | journal-article. doi: 10.1006/taap.1995.1070.
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells., Molecular pharmacology. 1994 Oct | journal-article. .
Ascorbate is the primary reductant of the phenoxyl radical of etoposide in the presence of thiols both in cell homogenates and in model systems., Biochemistry. 1994 Aug | journal-article. doi: 10.1021/bi00198a034.
Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells., Biochemical pharmacology. 1994 Aug | journal-article. doi: 10.1016/0006-2952(94)90282-8.
Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells., Molecular pharmacology. 1994 Jul | journal-article. .
Cytoplasmic metallothionein overexpression protects NIH 3T3 cells from tert-butyl hydroperoxide toxicity., The Journal of biological chemistry. 1994 May | journal-article. .
Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells., British journal of cancer. 1994 Apr | journal-article. doi: 10.1038/bjc.1994.131.
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells., Molecular pharmacology. 1994 Apr | journal-article. .
Interactions of phenoxyl radical of antitumor drug, etoposide, with reductants in solution and in cell and nuclear homogenates: electron spin resonance and high-performance liquid chromatography., Methods in enzymology. 1994 Jan | journal-article. doi: 10.1016/0076-6879(94)34134-6.
P-glycoprotein mediates profound resistance to bisantrene., Oncology research. 1994 Jan | journal-article. .
Altered gene expression in human leukemia K562 cells selected for resistance to etoposide., Biochemical pharmacology. 1993 Dec | journal-article. doi: 10.1016/0006-2952(93)90643-b.
Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line., Leukemia research. 1993 Dec | journal-article. doi: 10.1016/0145-2126(93)90161-d.
Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression., Cancer research. 1993 Aug | journal-article. .
Tyrosinase-induced phenoxyl radicals of etoposide (VP-16): interaction with reductants in model systems, K562 leukemic cell and nuclear homogenates., Free radical research communications. 1993 Jan | journal-article. doi: 10.3109/10715769309056527.
A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study., Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Jan | journal-article. doi: 10.1200/jco.1991.9.1.139.
Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients., Cancer research. 1990 Jul | journal-article. .
Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization., Cancer communications. 1989 Jan | journal-article. .
Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26)., Cancer research. 1987 Mar | journal-article. .
Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro., Cancer research. 1987 Feb | journal-article. .
Expressions of resistance and cross-resistance in teniposide-resistant L1210 cells., Cancer chemotherapy and pharmacology. 1987 Jan | journal-article. doi: 10.1007/bf00254563.
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro., Cancer research. 1985 Oct | journal-article. .
Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro., Biochemical pharmacology. 1985 Jul | journal-article. doi: 10.1016/0006-2952(85)90788-9.
Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro., Cancer research. 1985 Apr | journal-article. .
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage., Cancer research. 1984 Dec | journal-article. .
Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro., Cancer research. 1984 Aug | journal-article. .
Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro., Cancer research. 1984 Mar | journal-article. .
Characteristics of the accumulation of methotrexate polyglutamate derivatives in Ehrlich ascites tumor cells and isolated rat hepatocytes., Advances in experimental medicine and biology. 1983 Jan | journal-article. doi: 10.1007/978-1-4757-5241-0_17.
Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro., Cancer research. 1982 Sep | journal-article. .
Augmentation of the intracellular levels of polyglutamyl derivatives of methotrexate by vincristine and probenecid in Ehrlich ascites tumor cells., Cancer research. 1982 Jul | journal-article. .
Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro., The Journal of biological chemistry. 1982 Feb | journal-article. .